FeesSafety
Pluang+

GameChange Energy sues Nextpower for patent infringement over solar tracker technology

Market News
09 Sep 2026
PRNewsWire
View Source
Bearish
GameChange Energy sues Nextpower for patent infringement over solar tracker technology

GameChange Energy's subsidiary, GameChange Solar Corp., has filed a patent infringement lawsuit against Nextpower in Delaware, accusing them of violating a patent on its high-tilt stow technology used in solar trackers. The technology is designed to protect solar assets and maximize uptime, representing years of engineering investment. GameChange seeks to stop further infringement and obtain monetary damages. This legal action highlights the importance of protecting innovations in renewable energy infrastructure.

More News

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

Market News
Bullish
47 minutes ago
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

Market News
Bullish
48 minutes ago
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

Market News
Bullish
50 minutes ago
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Market News
Bullish
1 hour ago
Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App